Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study.

MLA

Clé, Diego V., et al. “Rabbit Antithymocyte Globulin Dose Does Not Affect Response or Survival as First-Line Therapy for Acquired Aplastic Anemia: A Multicenter Retrospective Study.” Annals of Hematology, vol. 97, no. 11, Nov. 2018, pp. 2039–46. EBSCOhost, https://doi.org/10.1007/s00277-018-3416-4.

APA

Clé, D. V., Atta, E. H., Dias, D. S. P., Lima, C. B. L., Bonduel, M., Sciuccati, G., Medeiros, L. A., De Oliveira, M. M., Blum Fonseca, P. B., Saad, S. T. O., Hamerschlak, N., Salvino, M. A., Garanito, M. P., Pazin-Filho, A., Scheinberg, P., & Calado, R. T. (2018). Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study. Annals of Hematology, 97(11), 2039–2046. https://doi.org/10.1007/s00277-018-3416-4

Chicago

Clé, Diego V., Elias H. Atta, Danielle S. P. Dias, Carlos B. L. Lima, Mariana Bonduel, Gabriela Sciuccati, Larissa A. Medeiros, et al. 2018. “Rabbit Antithymocyte Globulin Dose Does Not Affect Response or Survival as First-Line Therapy for Acquired Aplastic Anemia: A Multicenter Retrospective Study.” Annals of Hematology 97 (11): 2039–46. doi:10.1007/s00277-018-3416-4.